Key Drivers
- Strong Cash Flow
- Improving Margins
- Elevated Leverage
AIAI Summary
CHD has shifted from a defensive compounder to an execution-sensitive premium story: its 4%–5% organic-growth and 100–120 bp margin-expansion targets can justify upside only if sustained, while a >30x earnings valuation leaves little room for cost pressure, Zicam-related brand risk, or weaker volumes—wait for proof of delivery and a recovery above ~$98.50.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Improving Margins
- •Elevated Leverage
CHD delivers strong margins and cash conversion, but elevated valuation, leverage, and intangible exposure warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower-price trend
- •Key support holding
- •Resistance overhead
CHD is cautiously bearish after falling 2.7% over the last month from a $102.86 peak and remaining below its moving average; watch $93.94–$94.15 support versus $95.50–$96.00 resistance, with a break below support signaling downside and a move above $98.50–$99.80 improving momentum.
Declined sharply after reaching $102.86
Sentiment & News
Key News Insights:
- •Institutional Accumulation
- •Bullish Research
- •Insider Activity
Church & Dwight drew strong institutional buying and bullish upside attention, though insider option-related selling warrants monitoring.
The combined institutional demand and favorable analyst sentiment are supportive for CHD shares
Similar Companies in Consumer Defensive
Other companies in the same sector with AI ratings